BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Verma V, Lazenby AJ, Zheng D, Bhirud AR, Ly QP, Are C, Sasson AR, Lin C. Dosimetric parameters correlate with duodenal histopathologic damage after stereotactic body radiotherapy for pancreatic cancer: Secondary analysis of a prospective clinical trial. Radiother Oncol 2017;122:464-9. [PMID: 28089484 DOI: 10.1016/j.radonc.2016.12.030] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
Number Citing Articles
1 Haque W, Verma V, Lewis GD, Lo SS, Butler EB, Teh BS. Utilization of radiotherapy and stereotactic body radiation therapy for renal cell cancer in the USA. Future Oncol 2018;14:819-27. [PMID: 29527938 DOI: 10.2217/fon-2017-0536] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
2 Zschaeck S, Blümke B, Wust P, Kaul D, Bahra M, Riess H, Klein F, Sinn M, Pelzer U, Budach V, Ghadjar P. Dose-escalated radiotherapy for unresectable or locally recurrent pancreatic cancer: Dose volume analysis, toxicity and outcome of 28 consecutive patients. PLoS One 2017;12:e0186341. [PMID: 29023527 DOI: 10.1371/journal.pone.0186341] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
3 Lin C, Verma V, Lazenby A, Ly QP, Berim LD, Schwarz JK, Madiyalakan M, Nicodemus CF, Hollingsworth MA, Meza JL, Are C, Padussis J, Grem JL. Phase I/II Trial of Neoadjuvant Oregovomab-based Chemoimmunotherapy Followed by Stereotactic Body Radiotherapy and Nelfinavir For Locally Advanced Pancreatic Adenocarcinoma. Am J Clin Oncol 2019;42:755-60. [PMID: 31513018 DOI: 10.1097/COC.0000000000000599] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
4 Verma V, Simone CB 2nd. Approaches to stereotactic body radiation therapy for large (≥5 centimeter) non-small cell lung cancer. Transl Lung Cancer Res 2019;8:70-7. [PMID: 30788236 DOI: 10.21037/tlcr.2018.06.10] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
5 Loi M, Magallon-Baro A, Suker M, van Eijck C, Sharma A, Hoogeman M, Nuyttens J. Pancreatic cancer treated with SBRT: Effect of anatomical interfraction variations on dose to organs at risk. Radiother Oncol 2019;134:67-73. [PMID: 31005226 DOI: 10.1016/j.radonc.2019.01.020] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
6 Baumann M. The world needs new knowledge. Radiotherapy and Oncology 2018;126:1-2. [DOI: 10.1016/j.radonc.2017.12.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
7 Rao AD, Shin EJ, Meyer J, Thompson EL, Fu W, Hu C, Fishman EK, Weiss M, Wolfgang C, Burkhart R, He J, Kerdsirichairat T, Herman JM, Ding K, Narang A. Evaluation of a Novel Absorbable Radiopaque Hydrogel in Patients Undergoing Image Guided Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma. Pract Radiat Oncol 2020;10:e508-13. [PMID: 32151732 DOI: 10.1016/j.prro.2020.01.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Teng F, Meng L, Zhu F, Ren G. Dosimetric feasibility on hypofractionated intensity-modulated radiotherapy and simultaneous integrated boost for locally advanced unresectable pancreatic cancer with helical tomotherapy. J Gastrointest Oncol 2021;12:496-506. [PMID: 34012643 DOI: 10.21037/jgo-21-160] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Zhu X, Ju X, Cao Y, Shen Y, Cao F, Qing S, Fang F, Jia Z, Zhang H. Patterns of Local Failure After Stereotactic Body Radiation Therapy and Sequential Chemotherapy as Initial Treatment for Pancreatic Cancer: Implications of Target Volume Design. International Journal of Radiation Oncology*Biology*Physics 2019;104:101-10. [DOI: 10.1016/j.ijrobp.2019.01.075] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 11.0] [Reference Citation Analysis]
10 Kerdsirichairat T, Narang AK, Thompson E, Kim SH, Rao A, Ding K, Shin EJ. Feasibility of Using Hydrogel Spacers for Borderline-Resectable and Locally Advanced Pancreatic Tumors. Gastroenterology 2019;157:933-5. [PMID: 31306631 DOI: 10.1053/j.gastro.2019.07.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
11 Lin C, Verma V, Ly QP, Lazenby A, Sasson A, Schwarz JK, Meza JL, Are C, Li S, Wang S, Hahn SM, Grem JL. Phase I trial of concurrent stereotactic body radiotherapy and nelfinavir for locally advanced borderline or unresectable pancreatic adenocarcinoma. Radiother Oncol 2019;132:55-62. [PMID: 30825970 DOI: 10.1016/j.radonc.2018.11.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
12 Seshacharyulu P, Baine MJ, Souchek JJ, Menning M, Kaur S, Yan Y, Ouellette MM, Jain M, Lin C, Batra SK. Biological determinants of radioresistance and their remediation in pancreatic cancer. Biochim Biophys Acta Rev Cancer 2017;1868:69-92. [PMID: 28249796 DOI: 10.1016/j.bbcan.2017.02.003] [Cited by in Crossref: 27] [Cited by in F6Publishing: 33] [Article Influence: 6.8] [Reference Citation Analysis]
13 Mahadevan A, Moningi S, Grimm J, Li XA, Forster KM, Palta M, Prior P, Goodman KA, Narang A, Heron DE, Lo SS, Urbanic J, Herman JM. Maximizing Tumor Control and Limiting Complications With Stereotactic Body Radiation Therapy for Pancreatic Cancer. Int J Radiat Oncol Biol Phys 2021;110:206-16. [PMID: 33358561 DOI: 10.1016/j.ijrobp.2020.11.017] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
14 Zheng R, Wang C, Huang X, Lin Q, Huang D, Li XB, Huang H, Xu B. Chemotherapy-based split stereotactic body radiation therapy for borderline resectable and locally advanced pancreatic cancer: study protocol of a prospective, single-arm phase II trial. BMJ Open 2020;10:e039900. [PMID: 33154057 DOI: 10.1136/bmjopen-2020-039900] [Reference Citation Analysis]
15 Zhu X, Li F, Shi D, Ju X, Cao Y, Shen Y, Cao F, Qing S, Fang F, Jia Z, Zhang H. Health-related quality of life for gemcitabine and nab-paclitaxel plus radiotherapy versus gemcitabine and S-1 plus radiotherapy in patients with metastatic pancreatic cancer. Cancer Manag Res 2018;10:4805-15. [PMID: 30425574 DOI: 10.2147/CMAR.S166713] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
16 Verma V, Bhirud AR, Denniston KA, Bennion NR, Lin C. Quantification of renal function following stereotactic body radiotherapy for pancreatic cancer: secondary dosimetric analysis of a prospective clinical trial. Radiat Oncol 2017;12:71. [PMID: 28449702 DOI: 10.1186/s13014-017-0798-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
17 Wu G, Verma V, Haefner MF, Li S, Lin C. Feasibility and reproducibility of substituting oral contrast with water for duodenal volume delineation in patients undergoing pancreatic stereotactic body radiotherapy. J Gastrointest Oncol 2017;8:705-9. [PMID: 28890821 DOI: 10.21037/jgo.2017.04.03] [Cited by in F6Publishing: 1] [Reference Citation Analysis]